Country for PR: United States
Contributor: PR Newswire New York
Thursday, April 11 2019 - 23:45
Anpac Bio CDA Liquid Biopsy Technology Selected by FAST COMPANY 2019 "WORLD CHANGING IDEAS AWARD"
SACRAMENTO, California, April 11, 2019 /PRNewswire-AsiaNet/ --

The editors and judges of Fast Company Magazine selected Anpac Bio-Medical 
Science Company's ( 
), "Cancer Differentiation Analysis" ( 
) (CDA) Liquid Biopsy technology as an international, 2019 Health & Wellness 
"World Changing Ideas Award" ( 
) Honorable Mention recipient.

Photo - 

Photo - 

Logo -

Joining other "World Changing Ideas Award" (WCI) honorees such as: IBM, Intel, 
Amazon ( 
), NIKE, Boston Children's Hospital ( 
), Abbott, Microsoft, National Geographic, Gilead ( 
), Fitbit, Google, Siemens ( 
), Thermo Fisher Scientific ( 
), and The Bill & Melinda Gates Medical Research Institute ( 
), among others, Anpac Bio was recognized by Fast Company judges tasked with 
identifying, "…finished products and brave concepts that make the world 

WCI award recipients were selected from among over 2,000 nominations worldwide, 
based on feasibility and the potential for impact; and with a goal of awarding, 
"ingenuity and fostering innovation." 

Previously described as "game changing", and receiving the, "Breakthrough 
Innovation Award", at the World Nobel Prize Laureate Summit ( 
); and named, "Most Promising Cancer Screening Company", at the Global 
Precision Medicine Industry Awards; Anpac Bio was also recently selected by the 
United States Department of Commerce ( 
) as the, "Minority Health Firm of the Year", due to the company's remarkable, 
CDA liquid biopsy technology.

Anpac Bio pioneered liquid biopsy cancer screening research. Comprehensive 
research validity data from 140,000+ cases (to date), and 
independently-corroborated by world-renowned hospitals ( 
) and cancer research leaders ( 
), demonstrate CDA diagnostics consistently detects over 20 types of cancer, 
with 80%-90% sensitivity and specificity rates -- usually at the diseases' 
earliest stages. And it does so without any harmful patient side effects; 
generating far fewer "false positives"; at a cost substantially lower than 
traditional testing (such as imaging); and generating results within minutes of 
sample submission. Anpac Bio has filed over 200 CDA-related patent applications 
worldwide - 110 issued in 20 countries and regions (to date).

"Our Anpac Bio team is very proud to receive the 'World Changing Ideas' 
recognition from Fast Company," states Dr. Chris Yu ( 
), Anpac Bio CEO. "We believe the most important, world changing health ideas 
must be related to the early detection and prevention of disease. Our CDA 
technology was developed to achieve those goals. And we are now saving an 
average of two patients every week by catching their cancer at the earliest 
stages. We thank Fast Company for this great honor."

For further information:

SOURCE: Anpac Bio-Medical Science Company